1. Home
  2. GH vs SNN Comparison

GH vs SNN Comparison

Compare GH & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$82.29

Market Cap

13.3B

Sector

Health Care

ML Signal

HOLD

Logo Smith & Nephew SNATS Inc.

SNN

Smith & Nephew SNATS Inc.

HOLD

Current Price

$30.39

Market Cap

14.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GH
SNN
Founded
2011
1856
Country
United States
United Kingdom
Employees
N/A
16988
Industry
Medical Specialities
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.3B
14.3B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
GH
SNN
Price
$82.29
$30.39
Analyst Decision
Strong Buy
Hold
Analyst Count
19
2
Target Price
$119.79
$36.25
AVG Volume (30 Days)
2.1M
943.6K
Earning Date
05-07-2026
03-16-2026
Dividend Yield
N/A
2.42%
EPS Growth
6.74
N/A
EPS
N/A
N/A
Revenue
$982,021,000.00
N/A
Revenue This Year
$33.30
$8.58
Revenue Next Year
$28.27
$5.60
P/E Ratio
N/A
$64.97
Revenue Growth
32.88
N/A
52 Week Low
$36.36
$28.02
52 Week High
$120.74
$38.79

Technical Indicators

Market Signals
Indicator
GH
SNN
Relative Strength Index (RSI) 41.17 32.56
Support Level $82.33 N/A
Resistance Level $92.73 $33.89
Average True Range (ATR) 5.10 0.61
MACD -0.20 -0.28
Stochastic Oscillator 40.14 0.69

Price Performance

Historical Comparison
GH
SNN

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About SNN Smith & Nephew SNATS Inc.

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Share on Social Networks: